Brainstorm Cell Therapeutics Q1 2025 Financials Released
Ticker: BCLI · Form: 10-Q · Filed: May 15, 2025 · CIK: 1137883
| Field | Detail |
|---|---|
| Company | Brainstorm Cell Therapeutics Inc. (BCLI) |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, 10-Q, biotech
TL;DR
**Brainstorm Cell Therapeutics Q1 2025: Assets $7.9M, Liabilities $6.1M. Equity $1.7M.**
AI Summary
Brainstorm Cell Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $7.9 million and total liabilities of $6.1 million, resulting in total equity of $1.7 million. The filing also references warrants issued in July 2023 and valuation inputs such as share price, risk-free interest rate, and price volatility as of December 31, 2024.
Why It Matters
This filing provides a snapshot of Brainstorm Cell Therapeutics' financial health, including its assets, liabilities, and equity, which are crucial for investors to assess the company's stability and future prospects.
Risk Assessment
Risk Level: medium — The company has a relatively small asset base compared to its liabilities, indicating potential financial strain.
Key Numbers
- $7.9M — Total Assets (As of March 31, 2025)
- $6.1M — Total Liabilities (As of March 31, 2025)
- $1.7M — Total Equity (As of March 31, 2025)
Key Players & Entities
- BRAINSTORM CELL THERAPEUTICS INC. (company) — Filer
- 20250331 (date) — Reporting Period End Date
- $7,911,204 (dollar_amount) — Total Assets
- $6,141,762 (dollar_amount) — Total Liabilities
- $1,769,442 (dollar_amount) — Total Equity
- July 2023 (date) — Warrants Issuance Reference
FAQ
What was Brainstorm Cell Therapeutics' total equity as of March 31, 2025?
The company's total equity as of March 31, 2025, was $1,769,442.
What were the total assets reported by Brainstorm Cell Therapeutics for the period ending March 31, 2025?
Brainstorm Cell Therapeutics reported total assets of $7,911,204 for the period ending March 31, 2025.
What were the total liabilities for Brainstorm Cell Therapeutics as of March 31, 2025?
Total liabilities for Brainstorm Cell Therapeutics as of March 31, 2025, were $6,141,762.
What specific valuation inputs are mentioned in relation to the July 2023 Warrants?
The filing mentions share price, risk-free interest rate, and price volatility as valuation inputs for the July 2023 Warrants, with data as of December 31, 2024.
What is the company's primary business as indicated by its SIC code?
The company's Standard Industrial Classification (SIC) code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding BRAINSTORM CELL THERAPEUTICS INC. (BCLI).